Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Best Internet based Course for Learning Another Dialect: Which Stage Do You Like? - 2The Delight of Camper Vans: Choosing the One That Meets Your Requirements
- 3Stop the ‘good’ vs ‘bad’ snap judgments and watch your world become more interesting
- 42024 Style: The It-Things You Want in Your Closet
- 5Figure out How to Pick the Right Toothbrush for You
- Key takeaways from Sen. Bill Cassidy's interview on 'Face the Nation' with Margaret Brennan
- Hundreds of Gazans evacuated from Strip for medical treatment - COGAT
- No more attempts to free whale stranded off Germany, officials say
- Russia accidentally destroys its only way of sending astronauts to space
- Kate Hudson, 46, says she doesn't need long workouts to feel good
- Instructions to Improve Your Mental Exploration with Cutting edge Measurements
- Council removes proposal to rename park named after former president of Israel
- Members of Kenya-led security mission in Haiti were involved in rapes, U.N. says
- Belarusian parliament passes a bill to crack down on LGBTQ+ rights
